A61K 47/51
The non-active ingredient being a modifying agent
Official title: the non-active ingredient being a modifying agent
A61K47/51 (The non-active ingredient being a modifying agent) appears on 21,966 US grants and 36,569 published applications in this corpus.
Search patents in A61K- Granted patents
- 21,966
- Published applications
- 36,569
- Assignees
- 8,870
- Inventors
- 52,271
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 9 | 0 |
| 1977 | 11 | 0 |
| 1978 | 9 | 0 |
| 1979 | 6 | 0 |
| 1980 | 18 | 0 |
| 1981 | 11 | 0 |
| 1982 | 29 | 0 |
| 1983 | 20 | 0 |
| 1984 | 20 | 0 |
| 1985 | 23 | 0 |
| 1986 | 32 | 0 |
| 1987 | 40 | 0 |
| 1988 | 53 | 0 |
| 1989 | 73 | 0 |
| 1990 | 87 | 0 |
| 1991 | 98 | 0 |
| 1992 | 152 | 0 |
| 1993 | 146 | 0 |
| 1994 | 139 | 0 |
| 1995 | 164 | 0 |
| 1996 | 200 | 0 |
| 1997 | 307 | 0 |
| 1998 | 412 | 0 |
| 1999 | 346 | 0 |
| 2000 | 305 | 0 |
| 2001 | 298 | 104 |
| 2002 | 347 | 484 |
| 2003 | 292 | 796 |
| 2004 | 252 | 767 |
| 2005 | 225 | 793 |
| 2006 | 379 | 793 |
| 2007 | 297 | 710 |
| 2008 | 306 | 777 |
| 2009 | 373 | 914 |
| 2010 | 449 | 1061 |
| 2011 | 473 | 1043 |
| 2012 | 536 | 1002 |
| 2013 | 674 | 1162 |
| 2014 | 845 | 1467 |
| 2015 | 927 | 1633 |
| 2016 | 1045 | 1865 |
| 2017 | 1118 | 1786 |
| 2018 | 1169 | 1801 |
| 2019 | 1223 | 2026 |
| 2020 | 1241 | 2074 |
| 2021 | 1251 | 2258 |
| 2022 | 1139 | 2263 |
| 2023 | 1167 | 2381 |
| 2024 | 1179 | 2551 |
| 2025 | 1190 | 2313 |
| 2026 | 861 | 1745 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 47/62The modifying agent being a protein, peptide or polyamino acid7,345
- A61K 47/68The modifying agent being an antibody, an immunoglobulin or a fragment thereof7,141
- A61K 47/56The modifying agent being an organic macromolecular compound6,973
- A61K 47/54The modifying agent being an organic compound6,277
- A61K 47/52The modifying agent being an inorganic compound213
Recent patents
- Pharmaceutical composition containing anionic drug, and preparation method therefor6 Oct 2026US 12,752,010 B2Samyang Holdings Corporation
- Benzoheterocycle substituted tetrahydroisoquinoline compound6 Oct 2026US 12,752,011 B2Jiangxi Jemincare Group Co., Ltd
- EGFR degraders and associated methods of use6 Oct 2026US 12,752,012 B2BeOne Medicines | GmbH
- Muscle targeting complexes and formulations for treating facioscapulohumeral muscular dystrophy6 Oct 2026US 12,752,013 B2Dyne Therapeutics, Inc.
- Disruption of CD28-sialoside ligand complexes to enhance T cell activation6 Oct 2026US 12,752,014 B2The Scripps Research Institute
- Microbiome-based GABA Cream with Chondroitin Sulfate Transdermal Delivery System8 Oct 2026US 2026/0306531 A1
- Prefusion-stabilized human parainfluenza virus 3 f proteins8 Oct 2026US 2026/0306613 A1Board of Regents, The University of Texas System
- Nanoparticles for photoimmune therapy comprising photosensitizer and adjuvant, and usage thereof8 Oct 2026US 2026/0306632 A1Korea Institute of Science and Technology
- A combination therapy for cancer treatment8 Oct 2026US 2026/0306633 A1Purdue Research Foundation
- Pharmaceutical compositions comprising bupropion and cysteine8 Oct 2026US 2026/0306637 A1Antecip Bioventures II LLC
Most cited
By later US patents
- Non-immunogenic polypeptides2,007US 4,179,337 A1979
- Uncharged morpholino-based polymers having achiral intersubunit linkages1,700US 5,034,506 AAnti-Gene Development Group · 1991
- Polyhydroxyalkanoate compositions having controlled degradation rates1,516US 6,867,248 B1Metabolix, Inc. · 2005
- Polypeptide variants1,041US 6,194,551 B1Genentech, Inc. · 2001
- Backbone modified oligonucleotide analogs983US 5,602,240 ACiba-Geigy Corporation · 1997